FDA Grants Breakthrough Therapy Status to Ianalumab for Sjögren’s Disease

A promising new treatment for Sjögren’s disease may be on the horizon after the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to a drug called ianalumab. This designation is given to therapies that show strong early evidence of improving outcomes for serious conditions and helps speed up the development and review process.

Sjögren’s disease is a chronic autoimmune condition in which the immune system mistakenly attacks moisture-producing glands, leading to symptoms such as dry eyes, dry mouth, fatigue, and joint pain. In more severe cases, it can affect organs like the lungs and kidneys. Despite its impact, there are currently no approved targeted treatments specifically for this disease.

Ianalumab is a monoclonal antibody designed to target B cells, which play a central role in autoimmune diseases. It works through a dual mechanism: it both depletes harmful B cells and blocks signals that help them survive. This approach aims to reduce the underlying immune system dysfunction rather than just treating symptoms.

The Breakthrough Therapy designation is based on results from clinical trials, including large phase III studies known as NEPTUNUS-1 and NEPTUNUS-2. These trials showed that ianalumab led to meaningful improvements in disease activity and reduced the burden of symptoms for patients. Importantly, the safety profile of the drug was comparable to placebo, meaning it did not show significantly higher rates of serious side effects.

For patients, this development is significant because it signals potential progress toward the first targeted therapy specifically approved for Sjögren’s disease. If approved, ianalumab could change how the disease is managed, offering a treatment that addresses the root cause rather than only providing symptom relief.

Regulatory submissions are expected to begin in 2026, and patients and clinicians will be watching closely. While more steps remain before the drug becomes widely available, this milestone represents a hopeful advancement in Sjögren’s research and treatment.